Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events

Circulation

Volumn 99, Issue 16, 1999, Pages 2079-2084

  Biasucci, Luigi M ^a   Liuzzo, Giovanna ^a   Fantuzzi, Giamila ^b   Caligiuri, Giuseppina ^a   Rebuzzi, Antonio G ^a   Ginnetti, Francesca ^a   Dinarello, Charles A ^b   Maseri, Attilio ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Angina; Inflammation; Interleukins; Prognosis

Indexed keywords

INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 6; TROPONIN T; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CORONARY RISK; CYTOKINE PRODUCTION; FEMALE; HOSPITALIZATION; HUMAN; INFLAMMATION; MALE; PRIORITY JOURNAL; PROGNOSIS; UNSTABLE ANGINA PECTORIS;

EID: 0033609112     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.99.16.2079     Document Type: Article

References (39)

1. Liuzzo G, Biasucci LM, Gallimore JR, Grille RL, Rebuzzi AG, Pepys MB, Maseri A. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med. 1994;331:417-424.
2. Haverkate F, Thompson SG, Pyke SDM, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet. 1997;349:462-466.
3. Biasucci LM, Vitelli A, Liuzzo G, Altamura S, Caligiuri G, Monaco C, Rebuzzi AG, Ciliberto G, Maseri A. Elevated levels of interleukin-6 in unstable angina. Circulation. 1996;94:874-877.
4. Moser R, Schleiffenbaum B, Groscurth P, Fehr J. Interleukin-1 and tumor necrosis factor stimulate human vascular endothelial cells to promote transendothelial neutrophil passage. J Clin Invest. 1989;83:444-455.
5. Porat R, Poutsiaka DD, Miller LC, Granowitz EV, Dinarello CA. Interleukin-1 (IL-1) receptor blockade reduces endotoxin and Borrelia burgdorferi-stimulated IL-8 synthesis in human mononuclear cells. FASEB J. 1992;6:2482-2486.
6. Kaplanski G, Farnarier C, Kaplanski S, Porat R, Shapiro L, Bongrand P, Dinarello CA. Interleukin-1 induces interleukin-8 from endothelial cells by a juxtacrine mechanism. Blood. 1994;84:4242-4248.
7. Kurt-Jones EA, Beller DI, Mizel SB, Unanue ER. Identification of a membrane-associated interleukin-1 in macrophages. Proc Natl Acad Sci U S A. 1985;82:1204-1208.
8. Brody DT, Durum SK. Membrane IL-1: IL-1α precursor binds to the plasma membrane via a lectin-like interaction. J Immunol. 1989;143:1183-1187.
9. Hawrylowicz CM, Santoro SA, Platt FM, Unanue ER. Activated platelets express IL-1 activity. J Immunol. 1989;143:4015-4018.
10. Hawrylowicz CM, Howells GL, Feldmann M. Platelet-derived interleukin-1 induces human endothelial adhesion molecule expression and cytokine production. J Exp Med. 1991;174:785-790.
11. Kaplanski G, Porat R, Aiura K, Erban JK, Gelfand JA, Dinarello CA. Activated platelets induce endothelial secretion of interleukin-8 in vitro via an inlerleukin-1-mediated event. Blood. 1993;81:2492-2495.
12. Dinarello C. Biologic basis for interleukin-1 in disease. Blood. 1996;87: 2095-2147.
13. Cannon JG, Tompkins RG. Gelfand JA, Michie HR, Stanford GG, van der Meer JWM, Endres S, Lonnemann G, Corsetti J, Chernow B, Wilmore DW, Wolff SM, Dinarello CA. Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. J Infect Dis. 1990;161:79-84.
14. Fischer E, van Zee KJ, Marano MA, Rock CS, Kenney JS, Poutsiaka DD, Dinarello CA, Lowry SF, Moldawer LL. Interleukin-1 receptor antagonist circulates in experimental inflammation and in human disease. Blood. 1992;79:2196-2200.
15. Granowitz EV, Santos A, Poutsiaka DD, Cannon JG, Wilmore DA, Wolff SM, Dinarello CA. Circulating interleukin-1 receptor antagonist levels during experimental endotoxemia in humans. Lancet. 1991;338:1423-1424.
16. Mandrup-Poulsen T, Wogensen L, Jensen M, Svensson P, Nilsson P, Emdal T. Mølvig J, Dinarello CA, Nerup J. Circulating interleukin-1 receptor antagonist concentrations are increased in adult patients with thermal injury. Crit Care Med. 1995;23:26-33.
17. Pereira BJG, Shapiro L, King AJ, Falagas ME, Strom JA, Dinarello CA. Plasma levels of IL-β, TNFα and their specific inhibitors in undialyzed chronic renal failure. CAPD and hemodialysis patients. Kid Int. 1994;45: 890-896.
18. Gabay C, Smith MF, Eidlen D, Arend WP. Interleukin I receptor antagonist (IL-1Ra) is an acute-phase protein. J Clin Invest. 1997;99: 2930-2940.
19. Bresnihan B, Lookabaugh J, Witt K, Musikic P. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 1998;41:2196-2204.
20. Poutsiaka DD, Clark BD, Vannier E, Dinarello CA. Production of interleukin-1 receptor antagonist and interleukin-β by peripheral blood mononuclear cells is differentially regulated. Blood. 1991;78:1275-1281.
21. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, Ettlinger RE, Cohen S, Koopman WJ, Mohler K, Widmer MB, Blosch CM. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med. 1997;337:141-147.
22. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, Leeb B, Breedveld FC, Macfarlane JD, Long-Fox A, Charles P, Bijl H, Woody JN. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet. 1994;344:1105-1110.
23. Fisher CJJ, Slotman GJ, Opal SM, Pribble J, Bone RC, Emmanuel G, Ng D, Bloedow DC. Catalano MA. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. Crit Care Med. 1994;22:12-21.
24. Filonzi EL, Zoellner H, Stanton H, Hamilton JA. Cytokine regulation of granulocyte-macrophage colony stimulating factor and macrophage colony stimulating factor production in human arterial smooth muscle. Atherosclerosis. 1993;99:241-252.
25. Schaufelberger HD, Uhr MR, McGuckin C, Logan RPH, Misiewicz JJ, Gordon-Smith EC, Beglinger C. Platelets in ulcerative colitis and Crohn's disease express functional interleukin-1 and interleukin-8 receptors. Eur J Clin Invest. 1994;24:656-663.
26. Brody JI, Pickering NJ, Capuzzi DM, Fink GB, Can CA, Gomez F. Interleukin-1α as a factor in occlusive heart disease. Am J Clin Pathol. 1992;97:8-13.
27. Cannon JG, Nerad JL, Poutsiaka DD, Dinarello CA. Measuring circulating cytokines. J Appl Physiol. 1993;75:1897-1902.
28. Reinhart K, Wiegand-Löhnert C, Grimminger F, Kaul M, Withington D, Treacher J, Eckart J, Willats S, Bouza C, Krausch D, Stockenhuber F, Eiselstein J, Daum L, Kempeni J. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. Crit Care Med. 1996;24:733-742.
29. Casey LC, Balk RA, Bone RC. Plasma cytokines and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med. 1993;119:771-778.
30. LeMay LG, Otterness IG, Vander AJ, Kluger MJ. In vivo evidence that the rise in plasma IL-6 following injection of a fever-reducing dose of LPS is mediated by IL-1 beta. Cytokine. 1990;2:199-204.
31. Fantuzzi G, Ku G, Harding MW, Livingston DL, Sipe JD, Kuida K, Flavell RA, Dinarello CA. Response to local inflammation of IL-β converting enzyme-deficient mice. J Immunol. 1997;158:1818-1824.
32. Zheng H, Fletcher D, Kozak W, Jiang M, Hofmann K, Conn CC, Siszynski D, Grabiec C, Trumbauer MA, Shaw AR, Kostura MJ, Stevens K, Rosen H, North RJ, Chen HY, Tocci MG, Kluger MJ, van der Ploeg LHT. Resistance to fever induction and impaired acute-phase response in interleukin-β deficient mice. Immunity. 1995;3:9-19.
33. van der Poll T, van Deventer SJH, ten Cate H, Levi M, ten Cate JW. Tumor necrosis factor is involved in the appearance of interleukin 1 receptor antagonist in endotoxemia. J Infect Dis. 1994;169:665-667.
34. Mendall MA, Goggin PM, Molineaux N, Levy J, Toosy T, Strachan D, Camm AJ, Northfield TC. Relation of Helicobacter pylori infection and coronary heart disease. Br Heart J. 1994;71:437-439.
35. Saikku P, Leinonen M, Tenkanen L, Linnanmäki E, Ekman MR, Manninen V, Mänttüri M, Frick MH, Huttunen JK. Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann Intern Med. 1992;11:273-278.
36. Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm AJ. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation. 1997;96:404-407.
37. Liuzzo G, Biasucci LM, Rebuzzi AG, Gallimore JR, Caligiun G, Lanza G, Quaranta G, Monaco C, Pepys MB, Maseri. Plasma protein acute phase response in unstable angina is not induced by ischemic injury. Circulation. 1996;94:2374-2380.
38. Biasucci LM, Liuzzo G, Caligiuri G, van de Greef-W, Quaranta G, Monaco C, Rebuzzi AG, Kluft C, Maseri A. Episodic activation of the coagulation system in unstable angina does not elicit an acute phase reaction. Am J Cardiol. 1996;77:85-87.
39. Gurfinkel E, Bozovich G, Deroca A, Beck E, Mautner B. Randomised trial of roxithromycin in non-Q wave coronary syndromes: ROXIS pilot study. Lancet. 1997;350:404-407.